Based upon the evidence, leflunomide and consequently teriflunomide are candidates for personalized dosing for use in RA. The small unbound fraction of teriflunomide within the blood makes ...

Merck said that ARR for oral teriflunomide was lower than has been seen in other recent phase 3 trials, which made it harder for evobrutinib to show an advantage, but that will be small comfort to ...

Roche is running three late-stage studies, namely FENhance 1 and 2 trials in relapsing MS, comparing the drug to Sanofi's Aubagio (teriflunomide) and the FENtrepid trial in primary progressive MS ...

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...